Compositions and methods of nucleic acid-targeting nucleic acids
This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
1. A method for detecting if two complexes are in proximity to one another comprising:
contacting a first target nucleic acid with a first complex, wherein the first complex comprises a first site-directed polypeptide, a first modified nucleic acid-targeting nucleic acid comprising a first nucleic acid sequence complementary to the first target nucleic acid, and a first effector protein, wherein the first effector protein (i) is adapted to bind to the first modified nucleic acid-targeting nucleic acid, and (ii) comprises a first non-native sequence that comprises a first portion of an endonuclease split system;
contacting a second target nucleic acid with a second complex, wherein the second complex comprises a second site-directed polypeptide, a second modified nucleic acid-targeting nucleic acid comprising a second nucleic acid sequence complementary to the second target nucleic acid, and a second effector protein, wherein the second effector protein (i) is adapted to bind to the second modified nucleic acid-targeting nucleic acid, and (ii) comprises a second non-native sequence that comprises a second portion of an endonuclease split system; and
detecting an interaction between the first portion and the second portion, wherein (i) the split system forms an active endonuclease when the first portion of the endonuclease split system and the second portion of the endonuclease split system are in proximity, (ii) the interaction results in nucleic acid cleavage by the active endonuclease, and (iii) the detecting indicates the first complex and the second complex are in proximity to one another.
2. The method of claim 1 , wherein the detecting comprises determining the occurrence of a genetic mobility event.
3. The method of claim 2 , wherein the genetic mobility event comprises a translocation.
4. The method of claim 2 , wherein the genetic mobility event is a translocation between a BCR and an Abl gene.
5. The method of claim 1 , wherein the detecting indicates a genotype.
6. The method of claim 5 , wherein the genotype indicates a disease.
7. The method of claim 1 , wherein the first target nucleic acid comprises DNA and the second target nucleic acid comprises DNA.
8. The method of claim 1 , wherein genomic DNA comprises the first target nucleic acid and the second target nucleic acid.
9. The method of claim 1 , wherein the first modified nucleic acid-targeting nucleic acid, the second modified nucleic acid-targeting nucleic acid, or both the first modified nucleic acid-targeting nucleic acid and the second modified nucleic acid-targeting nucleic acid comprises RNA.
10. The method of claim 9 , wherein the first modified nucleic acid-targeting nucleic acid, the second modified nucleic acid-targeting nucleic acid, or both the first modified nucleic acid-targeting nucleic acid and the second modified nucleic acid-targeting nucleic acid further comprises DNA.
11. The method of claim 1 , wherein the first modified nucleic acid-targeting nucleic acid, the second modified nucleic acid-targeting nucleic acid, or both the first modified nucleic acid-targeting nucleic acid and the second modified nucleic acid-targeting nucleic acid comprises DNA.
12. The method of claim 1 , wherein the first site-directed polypeptide comprises an enzymatically inactive Cas9 polypeptide.
13. The method of claim 12 , wherein the second site-directed polypeptide comprises an enzymatically inactive Cas9 polypeptide.
14. The method of claim 1 , wherein the second site-directed polypeptide comprises an enzymatically inactive Cas9 polypeptide.
15. The method of claim 1 , wherein the first effector protein is a fusion comprising the first portion of the endonuclease split system and an enzymatically inactive Csy4 polypeptide.
16. The method of claim 15 , wherein the first modified nucleic acid-targeting nucleic acid comprises a Csy4 polypeptide binding site.
17. The method of claim 16 , wherein the second effector protein is a fusion comprising the second portion of the endonuclease split system and an enzymatically inactive Csy4 polypeptide, and the second modified nucleic acid-targeting nucleic acid comprises a Csy4 polypeptide binding site.
18. The method of claim 1 , wherein the second effector protein is a fusion comprising the second portion of the endonuclease split system and an enzymatically inactive Csy4 polypeptide.
19. The method of claim 18 , wherein the second modified nucleic acid-targeting nucleic acid comprises a Csy4 polypeptide binding site.
20. A kit for the method of claim 1 , comprising
a first modified nucleic acid-targeting nucleic acid or a polynucleotide encoding the first modified nucleic acid-targeting nucleic acid, the first modified nucleic acid-targeting nucleic acid comprising a first nucleic acid sequence complementary to a first target nucleic acid, and a first effector protein or a polynucleotide encoding the first effector protein, wherein the first effector protein (i) is adapted to bind to the first modified nucleic acid-targeting nucleic acid, and (ii) comprises a first non-native sequence that comprises a first portion of an endonuclease split system;
a second modified nucleic acid-targeting nucleic acid or a polynucleotide encoding the second modified nucleic acid-targeting nucleic acid, the second modified nucleic acid-targeting nucleic acid comprising a second nucleic acid sequence complementary to a second target nucleic acid, and a second effector protein or a polynucleotide encoding the second effector protein, wherein the second effector protein (i) is adapted to bind to the second modified nucleic acid-targeting nucleic acid, and (ii) comprises a second non-native sequence that comprises a second portion of an endonuclease split system; and
a reagent.